华东医药就VC005达成的独家商业化合作协议正式生效

Core Viewpoint - East China Pharmaceutical (华东医药) has entered into an exclusive commercialization agreement with Jiangsu Weikail (江苏威凯尔) for the oral formulation VC005, granting East China Pharmaceutical's subsidiary exclusive rights for commercialization in mainland China [1] Group 1 - East China Pharmaceutical's subsidiary, East China Pharmaceutical (Hangzhou) Co., Ltd., has officially signed the exclusive commercialization agreement on August 8 [1] - The agreement includes an initial payment of 50 million yuan and potential milestone payments up to 180 million yuan for registration [1]